AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion" is generating significant coverage in the Business category, with 4 articles from 4 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Whalesbook, GuruFocus, RAPS.org and The Business Journals. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Quick answers
Why is "AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion" trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- AbbVie sharpens immunology focus with $10.9 billion Apogee deal Reuters · 6h ago
- AbbVie to buy Waltham’s Apogee Therapeutics in nearly $11 billion deal The Boston Globe · 6h ago
- Done deal: AbbVie to buy Apogee for $10.9B FirstWord Pharma · 6h ago
- US Stocks Steady Near Record Highs; AbbVie to Buy Apogee for $10.9 Billion Whalesbook · 6h ago
- AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree GuruFocus · 6h ago
- Recon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapy RAPS.org · 6h ago
- AbbVie seals $10.9 billion deal to acquire biotech Apogee Therapeutics The Business Journals · 6h ago
Topics
Related trends
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics to expand its immunology drug portfolio.
Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today’s Market
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AbbVie’s biggest deal since 2019 could land soon
AbbVie has announced a $10.9 billion acquisition of Apogee Therapeutics, marking the pharmaceutical company's largest deal since 2019.
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
Pharmaceutical giant AbbVie is reportedly closing in on an $11 billion deal to acquire biotech firm Apogee Therapeutics.
Denisovan DNA influences the immune systems of modern Oceanians
Research indicates that Denisovan genetic material continues to impact the immune responses of individuals in the South Pacific.
The next two weeks could be a bumpy ride for U.S. stocks. Buy any dip, this strategist says.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.